Introduction: We sought to determine why some patients with coronary artery disease have more platelets that do not activate (express P-selectin on their surface) despite exposure in vitro to high concentrations of agonists and whether this finding is associated with altered platelet reactivity.

Methods: We assessed platelet activation and the proportion of young platelets with the use of flow cytometry in blood from 50 patients with coronary artery disease undergoing cardiac catheterization. Ultrastructural characteristics of platelets isolated with the use of a fluorescence activated cell sorter were assessed with the use of electron microscopy.

Results: Ultrastructural characteristics of platelets that did not exhibit surface expression of P-selectin in response to 50 nM thrombin delineated 2 groups; resting platelets devoid of glycogen stores and activated platelets. Because the activated platelets had shed their surface P-selectin we refer to them as 'previously activated' platelets. To estimate the proportion of 'previously activated' platelets we quantified the percentage of platelets that bound annexin-V but did not express P-selectin after exposure to 50 nM thrombin. The fraction of 'previously activated' platelets ranged from 0.3%-4.8% and correlated modestly though positively with the fraction of young platelets (r=0.41, p=0.003). Patients with more young platelets tended to have more 'previously activated' platelets and exhibited greater platelet reactivity.

Conclusions: A greater proportion of 'previously activated' platelets is associated with a greater fraction of young platelets and increased platelet reactivity. The presence of 'previously activated' platelets in circulating blood may be a marker of micro or macro thrombosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2007.06.004DOI Listing

Publication Analysis

Top Keywords

'previously activated'
24
activated' platelets
24
young platelets
20
platelets
19
activated platelets
12
patients coronary
12
coronary artery
12
artery disease
12
platelets activated
8
platelet reactivity
8

Similar Publications

After more than 15 years of decline, the Malaria epidemy has increased again since 2017, reinforcing the need to identify drug candidates active on new targets involved in at least two biological stages of the Plasmodium life cycle. The SUB1 protease, which is essential for parasite egress in both hepatic and blood stages, would meet these criteria. We previously reported the structure-activity relationship analysis of α-ketoamide-containing inhibitors encompassing positions P4-P2'.

View Article and Find Full Text PDF

Hardware neural networks could perform certain computational tasks orders of magnitude more energy-efficiently than conventional computers. Artificial neurons are a key component of these networks and are currently implemented with electronic circuits based on capacitors and transistors. However, artificial neurons based on memristive devices are a promising alternative, owing to their potentially smaller size and inherent stochasticity.

View Article and Find Full Text PDF

Three-dimensional genome architecture in intrahepatic cholangiocarcinoma.

Cell Oncol (Dordr)

January 2025

College of Life Science and Technology, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing, 100029, China.

Purpose: Intrahepatic cholangiocarcinoma (ICC) is a common primary hepatic tumors with a 5-year survival rate of less than 20%. Therefore, it is crucial to elucidate the molecular mechanisms of ICC. Recently, the advance of high-throughput chromosome conformation capture (Hi-C) technology help us look insight into the three-dimensional (3D) genome structure variation during tumorigenesis.

View Article and Find Full Text PDF

Unveiling cross-reactivity: implications for immune response modulation in cancer.

Brief Bioinform

November 2024

Program of Cell and Gene Therapy, Division of Experimental and Translational Research, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.

Antigen recognition by CD8+ T-cell receptors (TCR) is crucial for immune responses to pathogens and tumors. TCRs are cross-reactive, a single TCR can recognize multiple peptide-Human Leukocyte Antigen (HLA) complexes. The study of cross-reactivity can support the development of therapies focusing on immune modulation, such as the expansion of pre-existing T-cell clones to fight pathogens and tumors.

View Article and Find Full Text PDF

Generation of Human Chimeric Antigen Receptor Regulatory T Cells.

J Vis Exp

January 2025

Department of Microbiology and Immunology, Medical University of South Carolina; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina; Hollings Cancer Center, Medical University of South Carolina;

Chimeric antigen receptor (CAR) T-cell therapy has reshaped the face of cancer treatment, leading to record remission rates in previously incurable hematological cancers. These successes have spurred interest in adapting the CAR platform to a small yet pivotal subset of CD4 T cells primarily responsible for regulating and inhibiting the immune response, regulatory T cells (Tregs). The ability to redirect Tregs' immunosuppressive activity to any extracellular target has enormous implications for creating cell therapies for autoimmune disease, organ transplant rejection, and graft-versus-host disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!